NTRA earnings call: key takeaways

• Natera reported revenue of $794 million for Q3 2026, beating the $707.5 million consensus estimate (5:54)

Results vs expectations

What changed since last quarter

• The company raised full-year revenue guidance by $140 million at the midpoint, reflecting strong Q3 performance. (5:54)
• Gross margin improved to 65% in Q3, up 140 basis points from the previous quarter. (5:54)
• The CEO transition was announced, with Solomon Moskovich taking over leadership, signaling a continued focus on growth and execution. (2:23)

What analysts pressed on

• Whether the new LabCorp fetal recessive testing assay will impact the prenatal business. (57:25)
• How the company will manage gross margin pressure from newer products like Signatera genome and fetal focus. (47:48)
• The timing and contribution of the HCC reimbursement decision to future revenue. (45:16)

In their words

• We processed approximately 1.1 million tests in the third quarter, up more than 22% from about 894,000 a year ago. Steven Chapman (5:54)
• We generated $794 million in revenue, up approximately 34% over the $592 million that we reported in Q3 of last year. Steven Chapman (5:54)
• We're setting the goal to double revenues in the next three years. Steven Chapman (5:54)